Monte Rosa Therapeutics (GLUE) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$0.33.
- Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) fell 1379.31% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 11758.24%. This contributed to the annual value of -$0.98 for FY2024, which is 6258.42% up from last year.
- As of Q3 2025, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.33, which was down 1379.31% from -$0.15 recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.57 during Q1 2025, and its lowest value of -$0.71 during Q2 2023.
- In the last 3 years, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.43 in 2024 and averaged -$0.33.
- The largest annual percentage gain for Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) in the last 5 years was 20754.72% (2025), contrasted with its biggest fall of 1379.31% (2025).
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.57 in 2023, then soared by 131.82% to $0.18 in 2024, then tumbled by 281.92% to -$0.33 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.33 in Q3 2025, compared to -$0.15 in Q2 2025 and $0.57 in Q1 2025.